Steris Plc (ireland) · NYSE:STE
Steris Plc (ireland) — STERIS — Investor Presentation (August 2026)
21 slides from Steris Plc (ireland)'s investor presentation, August 2026
Slide 1: Investor Presentation
INVESTOR PRESENTATION August 2026
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to STERIS or its industry, products or activities that are intended to qualify for the protections afforded “f
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures We, at times, refer to financial measures which are considered to be “non-GAAP financial measures” under SEC rules. We, at times, also refer to our results of operations excluding certain transactions or amounts that are non-recurring or are not indicative of future resul
Slide 4: Why STERIS
Why STERIS • Durable, diversified, recurring revenue business focused on compliance in highly regulated environments. • Serving growth areas within healthcare – core Customers are healthcare providers, medical device and aseptic pharma manufacturers. • Conservatively leveraged with room to grow orga
Slide 5: STERIS at a Glance
STERIS at a Glance STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. Balanced 18,000 revenue stream Associates Consistent ~$6 BILLION drives profitability Worldwide performer ~75% Revenue in revenue and stability in U.S.
Slide 6: Serving Growth Areas Within Healthcare
Serving Growth Areas Within Healthcare Reporting Segments AST HEALTHCARE | A comprehensive offering for healthcare providers worldwide, 19% focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. Our products and services range from infection %
Slide 7: Healthcare Segment
Healthcare Segment Products / Services Key Financials ($mm) • Primary Customers of this segment are hospitals, surgery centers and 11% CAGR endoscopy centers; anywhere healthcare procedures take place. Revenue $3,085 $3,613 $3,879 $4,208 • We partner with our Customers to enable them to meet their p
Slide 8: Applied Sterilization Technologies (AST) Segment
Applied Sterilization Technologies (AST) Segment Products / Services Key Financials ($mm) 8% CAGR Provides contract sterilization and testing services for single-use products primarily for medical device and pharmaceutical manufacturers. $1,139 $914 $954 $1,039 Revenue +7% Crucial step in safely
Slide 9: Life Sciences Segment
Life Sciences Segment Products / Services Key Financials ($mm) *3% CAGR Sells primarily to pharmaceutical Customers, in particular to biopharma manufacturers to support the aseptic manufacturing environment through a mix $589 $537 $572 $542 of consumables, service and capital equipment. Revenue 7%
Slide 10: Consistent and Experienced Management Team
Consistent and Experienced Management Team Karen Burton Dan Carestio MC Fraser Ken Kohler Senior Vice President & President & Chief Executive Senior Vice President & Chief Senior Vice President & General Chief Financial Officer Officer Human Resources Officer Manager, AST – Joined STERIS 2004 – – Jo
Slide 11: Corporate Responsibility
Corporate Responsibility At STERIS, our Mission is to HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD. In fulfilling that Mission, we are committed to creating a sustainable future for our Customers, our people, our shareholders and the communities in which we work and live. Our Corporate Resp
Slide 12: History of Performance
History of Performance Total Revenue* Adjusted EBIT* Adjusted Operating Adjusted EPS* Margin* $5.9B $1.4B $10.17 23.3% $6.17 $699M $3.1B 22.5% 21 22 23 24 25 26 21 22 23 24 25 26 21 22 23 24 25 26 21 22 23 24 25 26 14% 5 YR CAGR 15% 5 YR CAGR +80 BPS 11% 5 YR CAGR Constant Currency Organic revenue a
Slide 13: Cash Flow Generation Provides Capacity for Growth
Cash Flow Generation Provides Capacity for Growth Free Cash Flow PRIORITIES FOR CAPITAL Operating Cash $1.3B 1 Maintain and Grow Dividend $983M $690M 2 Reinvest in the Business 3 Mergers and Acquisitions $451M 4 Share Repurchase 21 22 23 24 25 26 21 22 23 24 25 26 See Appendix for Reconciliation; Ye
Slide 14: Fiscal 2027 Outlook
Fiscal 2027 Outlook* • Total as reported revenue growth of approximately 7-8%. • Constant currency organic revenue growth of approximately 6-7%. • Adjusted earnings per diluted share of $11.10 – $11.30. • Assumes 25% effective adjusted tax rate. • Free cash flow of approximately $800 million. • Capi
Slide 15: Long-term Objectives
Long-term Objectives • Total revenue growth opportunity of mid-to-high single digits organically. • Healthcare growing mid-to-high single digits • AST growing high-single digits • Life Sciences growing mid-single digits • Fifty to seventy-five basis points of annual operating margin expansion driven
Slide 16: Appendix
Appendix 16
Slide 17: Appendix | Non-GAAP Reconciliation
Appendix | Non-GAAP Reconciliation 17
Slide 18: Appendix | Non-GAAP Reconciliation
Appendix | Non-GAAP Reconciliation 18
Slide 19: Appendix | Non-GAAP Reconciliation
Appendix | Non-GAAP Reconciliation 19
Slide 20: Appendix | Non-GAAP Reconciliation
Appendix | Non-GAAP Reconciliation 21
Slide 21: STERIS plc Investor Relations Contact
STERIS plc Investor Relations Contact: Julie Winter julie_winter@steris.com